Loading
A phase 3 trial testing Saruparib in prostate cancer, active and no longer recruiting.
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents is a phase 3 interventional study registered as NCT06120491, led by AstraZeneca, and active but no longer recruiting on the registry. Official title: A Randomised, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01). Planned enrolment is 1898 participants (actual). The study started in 2023-11-21 and primary completion is expected in 2027-09-30. No results have been posted on ClinicalTrials.gov.
Shares Saruparib, AstraZeneca, Prostate cancer.
Shares Saruparib, AstraZeneca.
Shares Saruparib, AstraZeneca, Prostate cancer.
Shares Saruparib, AstraZeneca, Prostate cancer.
Shares Saruparib, AstraZeneca, Prostate cancer.
Shares Metastatic hormone-sensitive prostate cancer, Prostate cancer.
Shares Metastatic hormone-sensitive prostate cancer, Prostate cancer.
Shares Metastatic hormone-sensitive prostate cancer, Prostate cancer.